

Monday, October 1st 2018(Day:1)

Session I: Update on Definition of ACLF

Time	Topic (7+8 min each)
8:00-8:15	Whether reversibility should be part of definition?
8:15-8:30	Will inclusion of terminology of 'First' presentation in definition improve clarity and homogeneity
8:30-8:45	Including organ failure in definition- for utility or futility?
8:45-9:00	Whether mortality should be part of definition?
9:00-9:20	Consensus statement

Session II: Acute Decompensation (AD)- Is it distinct from ACLF?

Time	Topic (7+8 min each)
9:20-9:35	Natural history and outcome ACLF
9:35-9:50	Natural history and outcome of Acute Decompensation
9:50-10:05	Acute Decompensation –differentiating from ACLF for clarity in definition
10:05-10:25	Consensus statement

10:25- 10:50 Coffee Break

Session III: Acute Insult and Chronic injury in ACLF-What is New?

Time	Topic (7+8 min each)
10:50-11:05	Infection and Sepsis
11:05-11:20	Drug Induced Liver Injury (Drugs, CAM & HDS)- with and without cirrhosis
11:20-11:35	Autoimmune Liver Disease – distinction between ACLF and ALF
11:35-11:50	Acute Variceal Bleed
11:50-12:05	Vascular diseases (PVT, HVOTO)
12:05-12:20	Impact of Comorbidities and Obesity
12:20-12:35	Changing trends for the aetiology of acute insult & chronic injury
12:35-12:55	Consensus statement

13:00-14:00 LUNCH

Session IV: Prognosis in ACLF patient- APASL dynamic model and others

Time	Topic (7+8 min each)
14:00-14:07	AARC score-applicability and validation
14:07-14:14	Korea
14:14-14:21	China
14:21-14:30	India
14:30-14:45	Discussion
14:45-15:00	Use of Organ dysfunction Vs Organ failure in ACLF for early risk stratification
15:00-15:15	Relevance of lactate in ACLF
15:15-15:30	Consensus statement

Session V: Hepatic encephalopathy in ACLF

Time	Topic (7+8 min each)
15:30- 15:45	HE in ACLF-spectrum and outcome
15:45-16:00	Relevance of Ammonia in prognostication and management of HE in ACLF
16:00-16:15	Spectrum of derangement, diagnosis, relevance and management
16:15-16:35	Consensus statement

16:35-17:05 COFFEE BREAK

Session VI: Infection in ACLF

Time	Topic (7+8 min each)
17:05-17:20	Site of infection-SBP, Pneumonia and others (cellulitis, UTI, SBE,Bacteremia)
17:20-17:35	Spectrum of infection and choice of antibiotics (community, nosocomial and 2 nd Hit)
17:35-17:50	Fungal infection-spectrum, outcome and choice of antifungal
17:50- 18:05	Consensus statement

20:00 Dinner

Tuesday, October 2nd 2018(Day:2)

Session VII : ACLF in Children (8:00-9:00)

Time	Topic (7+8 min each)
8:00-8:15	Is there a need of modified definition Children?
8:15-8:30	Prevalence, Spectrum and Natural History
8:30-8:45	Organ failure, Outcome and Prognostic scores
8:45-9:00	Consensus statement

Session VIII: Portal hypertension and its complications in ACLF

Time	Topic (7+8 min each)
9:00-9:15	Systemic, hepatic and pulmonary hemodynamics in ACLF
9:15-9:30	Variceal progression in ACLF and role of preemptive BB therapy
9:30-9:45	PICD-incidence, presentation, diagnosis and management
9:45-10:00	Consensus statement

10:00-10:30 Coffee Break

Session IX: Acute Kidney Injury in ACLF

Time	Topic (7+8 min each)
10:30-10:45	Spectrum, diagnosis of acute kidney injury and predictors of CKD development in ACLF
10:45-11:00	Pharmacotherapy (BB, Otreotide, midodrine, NE, Terlipressin, albumin, NAC, Pentoxyl, etc) for AKI in ACLF
11:00-11:15	RRT –indication, modality and outcome
11:15-11:30	Consensus statement

Session X: Liver Biopsy in ACLF

Time	Topic (7+8 min each)
11:30-11:45	Role of Liver biopsy in ACLF
11:45-12:00	Consensus statement

Session XI: Liver transplant

Time	Topic (7+8 min each)
12:00-12:15	Liver Transplant in ACLF-Asian Data
12:15-12:30	Prediction of need for transplant-when, which criteria
12:30-12:45	Right time for transplant in alcoholics with ACLF
12:45-13:00	Innovations in technique and management for improved transplant outcomes in ACLF
13:00-13:15	Consensus statement

13:15- 14:15 LUNCH BREAK

Session XII: Emerging Therapies in ACLF

Time	Topic (7+8 min each)
14:15-14:30	Plasmapheresis
14:30-14:45	Gut microbiome in ACLF AND Therapeutic implication
14:45-15:00	Regenerative and cell based therapy
15:00-15:20	Consensus statement

15:20-16:00 Presentation of New Clinical Trial Proposals

16:00-17:00 Presentation of the Final Consensus